Lupin’s alliance partner Concord gets approval for Mycophenolate Mofetil Tablets

06 Aug 2020 Evaluate

Lupin’s alliance partner Concord Biotech (Concord) has received approval from the United States Food and Drug Administration (USFDA) for Mycophenolate Mofetil Tablets USP, 500 mg, to market a generic version of CellCept Tablets of Roche Palo Alto LLC (Roche). Mycophenolate Mofetil Tablets are indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.

Mycophenolate Mofetil Tablets USP, 500 mg (RLD: CellCept) had an annual sales of approximately $96 million in the U.S. 

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.  

Lupin Share Price

2178.20 1.95 (0.09%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×